Madeleine covers PCR, nucleic acid amplification, and sample prep technologies for GenomeWeb.
The firm showed 98 percent sensitivity and 100 percent specificity across all major HCV genotypes in a recent study.
The assay could provide detection of HBV infection at early stages, potentially preventing progression to cirrhosis or hepatocellular carcinoma.
Using an immunoassay as an initial screening tool saved approximately $36,000 over multiplex PCR panel use alone when performed in a period of high flu prevalence.
The technology will measure cancer-associated miRNAs using optical amplification with quantum dots and photonic crystals.
The system will enable testing direct from a tube of blood using peptide nucleic acids-based methods to improve specificity.
The firm is also working on expanding its CTC capture capabilities beyond epithelial cells and will present multiple myeloma applications at an upcoming conference.
Although other groups have been developing noninvasive prenatal testing using digital PCR, BioCore claims to be the first to offer a test commercially.
Anitoa's handheld Maverick platform weighs one kilogram and comes with cloud-based analysis software.
The proposed diagnostic platform will be able to identify and determine resistance of bloodstream infections within three hours.
The quantitative paper-based DNA reader (qPDR) takes advantage of a recently discovered interaction between SYBR Green I and cellulose paper.
US News & World Report writes that genetic testing of lung tumors can help identify treatments for patients.
A team of researchers plans to sample Loch Ness for environmental DNA, according to Newsweek.
The New York Times writes about the appearance of mosaicism in healthy people.
In PNAS this week: insecticide resistance patterns Anopheles gambiae mosquito, transcriptome patterns in Pseudomonas aeruginosa during infection, and more.